Family Dollar Earnings Top These Hot Stock Morning Headlines
Regorafenib, a cancer drug from Onyx Pharmaceuticals (NASDAQ:ONXX) and Bayer AG, which treats metastatic colorectal cancer for patients in whom the disease has worsened after standard therapy, has been granted a priority review by the FDA – the FDA will review the drug in six months instead of the usual period of 10 months.
Don’t Miss: Apple SLURS Grow Louder.
The ICE futures exchange has started grading Brazilian coffee for delivery at the exchange effective March, and according to reports, may be discounting it by as much as 9 cents, making it unprofitable for Brazilian coffee producers to deliver on ICE. The 2012-13 crop is already trading soft, and arabica buyers such as Starbucks (NASDAQ:SBUX) are anticipating falling prices.
According to a regulatory filing by Jones Soda (NASDAQ:JSDA) its Chief Executive William Meissner and board chairman Richard Eiswirth are stepping down, and the company’s chief financial officer position will be removed effective June 30 in order to cut costs.
Family Dollar (NYSE:FDO) saw comparable store sales rise 5 percent while SG&A expenses cut from 27.7 percent to 27.4 percent; for the current quarter it expects comparable store sales growth of 5 percent to 7 percent with an EPS of $0.71 to $0.81.